Patient-Specific Metrics for Scan Parameter Adaption in CT-Based Lung Cancer Screening

Johannes Schneider, Stefan Sawall, and Marc Kachelrieß

German Cancer Research Center (DKFZ) Heidelberg, Germany www.dkfz.de/ct



### Lung Cancer – Significance

Women	Men	Women	Men
Breast 30.5%	25.1 % Prostate	Breast 17.6 %	22.2 % Lung
Colon and rectum 10.5%	13.0% Lung	Lung 16.3 %	12.3 % Prostate
Lung 9.8%	11.7% Colon and rectum	Colon and rectum 10.2 %	10.5 % Colon and rectum
Malignant melanoma of the skin 4.9%	4.8 % Bladder	Pancreas 9.0 %	7.5 % Pancreas
Uterus 4.7%	4.7% Malignant melanoma of the skin	Ovaries 5.0%	4.5 % Liver
Pancreas 4.3 %	3.9% Pancreas	Leukaemia 3.4%	4.0 % Stomach
Non-Hodgkin lymphoma 3.6 %	3.9% Non-Hodgkin lymphoma	Stomach 3.2 %	3.8 % Leukaemia
Ovaries 3.1 %	3.6 % Kidney	Non-Hodgkin lymphoma 3.0%	3.6 % Oesophagus
Leukaemia 2.4%	3.5 % Oral cavity and pharynx	Liver 2.6 %	3.2 % Non-Hodgkin lymphoma
Stomach 2.3 %	3.5% Stomach	Uterus 2.6 %	3.2% Oral cavity and pharynx
Kidney 2.1 %	3.0% Leukaemia	Central nervous system 2.5%	
	2.6 % Liver	Gallbladder and biliary tract 2.0%	2.7% Central nervous system
Bladder 2.0 %	2.2 % Oesophagus		2.5% Kidney
	1.6 % Central nervous system	Bladder 1.8 %	1.8% Multiple myeloma
Thyroid gland 1.7 % 📃	1.6 % Testis	Multiple myeloma 1.8 % 📃	1.4% Malignant melanoma of the skin
Central nervous system 1.4% 📃	1.4% Multiple myeloma	Ćervix 1.5%	1.4% Gallbladder and biliary tract
. Vulva 1.3 % 📃	1.0% Larynx	Oesophagus 1.3 % 📃	0.9% Larynx
Liver 1.3 %	1.0 % Gallbladder and biliary tract	Oral cavity and pharynx 1.3 % 📃	0.8 % Mesothelioma
Multiple myeloma 1.3 % 📃	0.9 % Soft tissue without Mesothelioma	Malignant melanoma of the skin 1.1% 📃	0.7 % Soft tissue without Mesothelioma
Gallbladder and biliary tract 1.1 % 📃			0.3 % Small intestine
Soft tissue without Mesotheĺioma 0.9 % 📃		Soft tissue without Mesothelioma 0.9 % 📃	0.2% Thyroid gland
	0.6 % Hodgkin lymphoma	Thyroid gland 0.4%	
	0.5 % Mesothelioma	Ánus 0.3 %	0.2 % Bone and articular cartilage
	■ 0.4 % Renal pelvis and ureter	Small intestine 0.3 %	
Hodgkin lymphoma 0.4 %		Mesothelioma 0.3 %	
Renal pelvis and ureter 0.3 %		Larynx 0.2%	l 0.2 % Renal pelvis and ureter
	0.3% Breast	Bone and articular cartilage 0.2 %	0.1% Hodgkin lymphoma
	0.3 % Nasal cavity, nasal sinuses and middle ear	Vagina 0.2 % I	0.1% Breast
Nasal cavity, nasal sinuses and middle ear 0.2 %	0.2% Bone and articular cartilage		0.1% Eye
Vagina 0.2%			l 0.1 % Nasal cavity, nasal sinuses and middle ear
Bone and articular cartilage 0.2%		Hodgkin lymphoma 0.1 % I	
Mesothelioma 0.1 %		Nasal cavity, nasal sinuses and middle ear 0.1 % I	
36 30 24 18 12 6 0	0 6 12 18 24 30	<u>30</u> 24 18 12 6 0	0 6 12 18 24 30

**Most frequent** tumour sites as percent of all incident cancer cases in Germany 2020. Adapted from.

Most frequent tumour sites when cancer was cause of death in Germany 2020. Adapted from.



36

### Low Dose CT Screening – Trial Results

#### **Benefits:**

- Early detection leads to more effective treatment
- Reduction in lung cancer mortality
- 15% relative reduction in lung cancer mortality compared to chest X-ray
   Risks:
- Cumulative exposure
- False positives
- Overdiagnosis
- Risk-Benefit: The benefits for high-risk populations outweigh the risks

RCT	N	Comparison	<b>CTDI</b> <sub>max</sub>
NLST USA	53,454	LDCT vs. chest X-ray	≈ 4 mGy*
NELSON Netherlands and Belgium	15,822	LDCT vs. no screening	0.8, 1.6, 3.2 mGy
DLCST Denmark	4,104	LDCT vs. no screening	?
LUSI Germany	4,052	LDCT vs. no screening	?
MILD Italy	4,099	Annual vs. biennial LDCT	?



### **Technical Demands by the BfS**


Parameter	Requirement	Comment	
Dose conversion	k = 0.019  mSv/mGy/cm	$D_{\rm eff} = k \cdot {\sf DLP}$	
Topogram CTDI	≤ 20% of screening CTDI	Use additional prefilter	
Scan length	Adapt to lung	Not longer than lung	
Scan time	≤ 15 s	Breath hold required	
Spiral pitch value	According to vendor	Moderate to high	
Rotation time	≤ 1 s		
Screening CTDI dose cap	≤ 1.3 mGy	For BMI = 26 kg/m <sup>2</sup>	
Additional prefilter	Yes	At least for BMI $\leq$ 40 kg/m <sup>2</sup>	
TCM, auto kV-selection	Yes	TCM in $\alpha$ and z	
Dynamic collimation	Yes, if at least 64 detector rows	To avoid overbeaming	
Reconstruction	Iterative or deep learning		
Spatial resolution	Between 0.8 and 1.0 mm	For low contrasts (150 HU)	
Slice thickness	≤ 0.7 mm		
Voxel size (isotropic)	≤ 70% of spatial resolution		
Image noise	Low enough to be diagnostic		
Exposure parameters and dose levels are to be adapted to patient size!			

Bundesamt für Strahlenschutz. "Lungekrebsfrüherkennung mittes Niedrigdosis Computertomographie". Bundesanzeiger (2021).



#### BMI – A Representative Patient Size Metric for Phantom Assessments?

## **1.3 mGy CTDI**<sub>vol</sub> dose cap for a reference patient with a BMI of 26 kg/m<sup>2</sup>.





#### Aim

To use our semiantropomorphic thorax phantom for QA, the phantom must be connected with patient size properties (the BfS' 26 kg/m<sup>2</sup>). We do this by:

- 1. <u>Determining</u> the equivalent BMI of a thorax phantom such that the phantom with equivalent BMI of that of a patient yield similar image quality.
- 2. Evaluating how the recommended  $CTDI_{vol}$  dose cap should be adapted for patients with varying BMIs in lung cancer scans.
- 3. <u>Identifying</u> a metric for varying patient and phantom sizes that can be used to estimate the necessary  $\text{CTDI}_{\text{vol}}$  to achieve a desired image quality.




#### Patient and Phantom Acquisition and Reconstruction Parameters

	Dataset	Patients	Phantoms	
	Number of scans	100	9	
	Voltage	100 or 120 kV	120 kV	
	Pitch	0.6 or 1.2	1.2	
	Collimation	64 · 0.6 mm		
$\left\{ \right\}$	CT-Model	Somatom Definition Flash		
	CTDI <sub>vol</sub>	0.5 mGy – 14 mGy	1.0 mGy, 1.3 mGy, 1.6 mGy	
	Reconstruction type	FBP/ Safire 3	FBP/ Safire 3	
	Voxel size	0.3 mm		
Ì	Viewing thickness	3.0 mm		
	Kernel	BI57		

Acquisition


Reconstruction





#### **Manual Dose Adaption**

For FBP, noise is influenced by patient size and tube output.




The necessary dose output CTDI<sup>rel</sup><sub>vol</sub> to achieve image quality 
 <sup>ref</sup> is then:
 In the second second

$$m g\,CTDI_{
m vol}^{
m rel} \propto s$$

attenuation




#### Example Surrogate for Size s



Boone et al. "Size-Specific Dose Estimates (SSDE) in pediatric and adult body CT examinations". AAPM (2011). McCoullough et al. "Use of Water Equivalent Diameter for Calculating Patient Size and Size–Dependent Dose Estimates (SSDE) in CT". AAPM (2014).



#### **Calibration Curve: BMI as a Function of WED**




Phantom size	WED	BMI (from linear fit)	
Small	20.6 cm	19.6 kg/m²	
Medium	26.7 cm	26.8 kg/m²	
Large	32.4 cm	33.5 kg/m²	

Calibration curve between the WED and the BMI based on 100 patients.



### CTDI as a Function of WED to Achieve a Given Image Noise (here: 70 HU)



Phantom size	WED	Equivalent BMI	CTDI for FBP	CTDI for Safire 3
Small	20.6 cm	19.6 kg/m²	0.63 mGy	0.30 mGy
Medium	26.7 cm	26.8 kg/m²	1.81 mGy	0.88 mGy
Large	32.4 cm	33.5 kg/m²	4.88 mGy	2.41 mGy

Correlation between the WED and the required CTDI<sub>vol</sub> (log-scale) to achieve 70 HU image noise in lung scans.

#### **Conclusions and Outlook**

- Size in CT-based lung scans and needs to be properly accounted for.
- Assuming the attenuation based WED the dose to achieve a 70 HU image noise can be estimated by

# If reconstructed using FBPIf reconstructed using Safire 3 $CTDI_{vol}^{rel} = exp\left(\frac{0.174}{cm} \cdot WED - 4.052\right)$ $CTDI_{vol}^{rel} = exp\left(\frac{0.177}{cm} \cdot WED - 4.856\right)$

• For phantom assessments, the equivalent 'BMI' can be estimated by comparison of WED with BMI.

$$BMI = \frac{1.177 \text{ kg}}{\text{m}^2 \text{ s}} \text{ WED} - 4.624 \frac{\text{kg}}{\text{m}^2}$$



#### **Thank You!**

- This presentation will soon be available at www.dkfz.de/ct.
- Job opportunities through DKFZ's international PhD or Postdoctoral Fellowship programs (marc.kachelriess@dkfz.de).
- Parts of the reconstruction software were provided by RayConStruct<sup>®</sup> GmbH, Nürnberg, Germany.

